Bibliography
- Rai K, Peterson B, Appelbaum F, Fludarabine compared with chlorambucil as primary therapy for CLL. N Engl J Med 2000;343:1750-7
- Byrd J, Peterson BL, Morrison VA, Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712. Blood 2003;101(1):6-14
- Keating M, O'Brien S, Albitar M, Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4079-88
- Hallek M, Fischer K, Fingerle-Rowson G, Addition of Rituximab to Fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet 2010;376(9747):1164-74
- Chang JE, Kahl BS. Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother 2012;13(10):1495-1505
- Knauf W, Lissichkov T, Aldaoud A, Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27(26):4378-84
- Fischer K, Cramer P, Stilgenbauer S, Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG). Blood (ASH Annual Abstracts) 2009;114:abstract 205
- Wierda W, Kipps TJ, Mayer J, Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28(10):1749-55
- Chanan-Khan A, Miller KC, Musial L, Clinical Efficacy of Lenalidomide in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: results of a Phase II study. J Clin Oncol 2006;24:5343-9
- Ferrajoli A, Lee BN, Schlette EJ, Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7
- Ujjani C, Jamshed S, Fitzpatrick K, Lenalidomide following rituximab and fludarabine in untreated CLL. J Clin Oncol (ASCO Annual Meeting Abstracts) 2011;29: abstract 6558
- O'Brien S, Burger J, Blum K, The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. Blood (ASH Annual Abstracts) 2011;118:abstract 983
- Furman R, Byrd J, Brown J, CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood (ASH Annual Abstracts) 2010;116:abstract 55